Telix Pharmaceuticals is an Australian radiopharmaceutical company built around prostate cancer, where its gallium-68 PSMA-11 imaging agent Illuccix reached the market and now anchors a growing therapeutic pipeline. The company's lead therapy candidate is TLX591 (rosopatamab tetraxetan), a lutetium-177-labeled PSMA-targeting radio-antibody-drug conjugate.
At ASCO 2026, Telix reported that the Part 1 lead-in of its ProstACT Global Phase 3 trial met its primary safety objectives in patients with PSMA-positive metastatic castration-resistant prostate cancer, clearing the path to the randomized portion. ProstACT positions TLX591 against Novartis's Pluvicto (lutetium-177 PSMA-617), the small-molecule PSMA radioligand that defined the category, with the antibody-conjugate format offering a different pharmacokinetic profile. Telix is also developing imaging and therapy candidates in renal and other cancers.
On September 21, 2026 (Australian time), Telix agreed to merge with Germany's ITM Isotope Technologies Munich for $1.65 billion upfront on a cash-free, debt-free basis, including 105.8 million Telix shares, plus up to $700 million tied to regulatory approvals and sales milestones for ITM-11 (177Lu-edotreotide). ITM-11 is a somatostatin receptor-targeted treatment for gastroenteropancreatic neuroendocrine tumors that completed the Phase 3 COMPETE trial and has fully enrolled a second Phase 3 study, COMPOSE. Telix describes ITM as the world's leading supplier of therapeutic radioisotopes and the only producer of globally scaled commercial-grade lutetium-177, with actinium-225 and terbium-161 production as well. The deal needs Telix shareholder and regulatory approvals and is expected to close by the end of fiscal 2026.
Stories here cover Telix trial readouts, the ITM merger integration, and the PSMA and somatostatin radioligand races. See #prostact, #psma, #itm-isotope-technologies-munich, and #radioligand for adjacent threads.
Telix Pharmaceuticals announced late on September 20, 2026 U.S. Eastern time (September 21 in Australia) an agreement to merge with Germany's ITM Isotope Technologies Munich for $1.65 billion upfront on a cash-free, debt-free basis, including 105.8 million Telix shares, plus up to $700 million tied to regulatory approvals and sales milestones. The milestones are linked to ITM-11 (177Lu-edotreotide), a somatostatin receptor-targeted treatment for gastroenteropancreatic neuroendocrine tumors that completed the Phase 3 COMPETE trial and has fully enrolled a second Phase 3 study, COMPOSE. Telix describes ITM as the world's leading supplier of therapeutic radioisotopes and the only producer of globally scaled commercial-grade lutetium-177, with actinium-225 and terbium-161 production as well. The deal needs Telix shareholder and regulatory approvals and is expected to close by the end of fiscal 2026.
Telix Pharmaceuticals Limited (NASDAQ: TLX) reached its FDA Prescription Drug User Fee Act (PDUFA) action date of Friday September 11, 2026 for TLX101-Px (Pixclara, floretyrosine F 18, also called 18F-FET), an investigational positron emission tomography (PET) imaging agent designed to help distinguish recurrent or progressive glioma from treatment-related changes in adult and pediatric patients with previously treated glioma. The FDA had accepted the resubmitted NDA in April 2026 following an earlier complete response letter. Pixclara carries FDA Fast Track and Orphan Drug designations. Standard MRI post-treatment surveillance struggles to differentiate true tumor progression from pseudoprogression or radiation necrosis; a PET imaging agent that binds selectively to actively metabolizing tumor cells addresses a substantial diagnostic gap. If approved, Pixclara would be one of the first tumor-specific glioma PET agents to enter the U.S. market. The company had not confirmed the FDA action outcome as of end of Friday U.S. business hours; investors were watching for a Monday morning announcement.
ASCO's Sunday education and poster sessions in Chicago set up the meeting's densest peptide-oncology day on Monday, June 1, when Bicycle Therapeutics presents Duravelo-2 (zelenectide pevedotin in first-line urothelial cancer, Abstract 4516), Mayo Clinic presents the TPIV200 folate-receptor-alpha vaccine in triple-negative breast cancer (Abstract 536), and Telix presents ProstACT Global PSMA radioligand data. Corbus CRB-701 and BioVaxys MVP-S round out the targeted-conjugate and vaccine slate.
ASCO 2026 Day 2 in Chicago continued the meeting's peptide-and-targeted-conjugate oncology programming. Saturday May 30 brought the Immutep eftilagimod alfa survival pooled analysis and the ImPact Biotech padeliporfin VTP pancreatic data, alongside the Bicycle Therapeutics zelenectide pevedotin dose-optimization poster (Abstract 4567, May 31) approaching. The meeting's heaviest peptide-mechanism day is Monday June 1: Bicycle Duravelo-2 zelenectide pevedotin + pembrolizumab oral presentation in 1L urothelial (Abstract 4516, 8:30 AM CT); Mayo Clinic TPIV200 folate-receptor peptide vaccine in triple-negative breast cancer (Abstract 536, 1:30 PM CT); Telix ProstACT PSMA radioligand Phase 3 Part 1; Sapience lucicebtide GBM poster. The Corbus CRB-701 Nectin-4 ADC data (42.9% OPSCC / 34.4% cervical) landed Friday May 29. The targeted-conjugate categories — Nectin-4, PSMA, B7-H3, FAP, SSTR2 — remain the densest peptide-adjacent oncology competition, with the bulk of definitive readouts concentrated in the meeting's back half through June 2.
Telix Pharmaceuticals reported ProstACT Global Phase 3 Part 1 data at ASCO 2026 as a late-breaking presentation. TLX591-Tx (lutetium-177 rosopatamab tetraxetan) — a PSMA-targeted lutetium radio-antibody-drug conjugate — met its primary safety objectives in the safety and dosimetry lead-in, demonstrating an acceptable tolerability profile with no new safety signals when combined with enzalutamide (Xtandi), abiraterone (Zytiga), or followed by docetaxel in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). ProstACT Global is an international Phase 3 trial evaluating TLX591-Tx plus standard of care versus standard of care alone. The drug sits in the PSMA-targeted radioligand class alongside Novartis's approved Pluvicto (lutetium-177 PSMA-617, a peptide-based radioligand), but uses an antibody rather than a small-molecule peptide as the targeting vector. The PSMA radioligand field — Pluvicto, ProstACT, plus the Aktis AKY-2519 B7-H3 miniprotein radioconjugate covered earlier this week — is one of the fastest-growing targeted-conjugate categories in oncology.